Abstract
Introduction HIV-negative adolescent girls and young women (AGYW), and male partners, have disproportionately high HIV incidence in many African countries. We used a new HIV Prevention Cascade (HPC) approach to quantify levels of, and barriers to, prevention method use to guide interventions to increase effective uptake of primary HIV prevention.
Methods Data from the Manicaland HPC pilot study (2018-19; N=9803) in Zimbabwe were used to measure levels of sexual risk behaviour and construct HPCs for male condom, PrEP (females), VMMC (males) and combination prevention use by HIV-negative sexually-active AGYW (15-24-years) and male partners (15-29-years).
Results 19% of AGYW (N=1140) and 37% of young men (N=955) who had started sex reported one or more HIV risk behaviour and met the definition of the priority populations for HIV prevention. Of these, 63% of females and 87% of males were motivated to use an HIV prevention method, 28% and 63% had access to a method, and 16% and 53% used a method. Male condoms were the most commonly used prevention method, accounting for 97% of use in females and 55% in males. Barriers to motivation, access and capacity to use were reported for all priority populations and methods. Some barriers were common across HPCs (e.g. lack of risk perception, social unacceptability, and lack of acceptable provision); others were specific to particular prevention methods or priority populations (e.g. lack of availability).
Conclusion HIV risk behaviours were commonly reported, but use of prevention methods is low in young people in Manicaland. Population survey measurements of HPCs revealed large gaps in all steps in the cascade (lack of motivation, lack of access and lack of capacity to use prevention) but also provided information on the reasons for these gaps that can aid in designing interventions that reduce new infections.
Competing Interest Statement
Simon Gregson declares shareholdings in pharmaceutical companies GlaxoSmithKline and Astra Zeneca. All other authors have no conflicts of interest to declare.
Funding Statement
This work was supported by the Bill and Melinda Gates Foundation (BMGF) (INV09999) and the National Institute of Mental Health (NIMH) (R01MH11456201). LM, SG, TBH, JWI-E and CN acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has obtained ethical approvals from the Medical Research Council of Zimbabwe (reference number: MRCZ/A/2243), the Biomedical Research and Training Institute, Zimbabwe Institutional Review Board (reference number: AP140/2017) and the Imperial College London Research Ethics Committee (reference number: 17IC4160)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data access statement
Due to the sensitive nature of data collected, including information on HIV status, treatment and sexual risk behaviour, the Manicaland Centre for Public Health does not make full analysis datasets publicly available. Summary datasets of household and background sociodemographic individual questionnaire data, covering rounds 1-8 (1998-2021) of the Manicaland General Population HIV Sero-Survey, are publicly available for download via the Manicaland Centre for Public Health website here - http://www.manicalandhivproject.org/data-access.html. Quantitative data used for analyses produced by the Manicaland Centre for Public Health are available on request following completion of a data access request form here - http://www.manicalandhivproject.org/data-access.html. Additionally, summary HIV incidence and mortality data spanning rounds 1-6 (1998-2013), created in collaboration with the ALPHA Network are available via the DataFirst Repository here - https://www.datafirst.uct.ac.za/dataportal/index.php/catalog/ALPHA/about
